The phenomenon of preconditioning today

Hellenic Journal of Cardiology

Volumn 46, Issue 1, 2005, Pages 1-4

  Kremastinos, Dimitrios Th ^a,b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Ischaemia; Myocardial infarction; Preconditioning

Indexed keywords

ADENOSINE; GLIBENCLAMIDE; GLIMEPIRIDE; NICORANDIL; POTASSIUM CHANNEL; PRAVASTATIN; THYROXINE;

ANGINA PECTORIS; CLINICAL TRIAL; COLLATERAL CIRCULATION; CORONARY ARTERY THROMBOSIS; DIABETES MELLITUS; EDITORIAL; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIA; MORTALITY; NONHUMAN; UNSTABLE ANGINA PECTORIS; COMPARATIVE STUDY; FEMALE; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; MALE; METHODOLOGY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FEMALE; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 17844398483     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Editorial

References (32)

1. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.
2. Przyklenk K, Kloner RA: Ischemic preconditioning: exploring the paradox. Progr Cardiovasc Disease 1998; 40: 517-547.
3. Schulz R, Behrends M, Downey JM, Heusch G: Signal transduction of ischemic preconditioning. Cardiovasc Res 2001; 52: 181-198.
4. Dekker LRC, Rademaker H, Vermeulen JT, Opthof T, Coronel R, Spaan JAE, Janse MJ: Cellular uncoupling during ischemia in hypertrophied and failing rabbit ventricular myocardium. Effects of preconditioning. Circulation 1998; 97: 1724-1730.
5. Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO. Prevention conference VI: Diabetes and cardiovascular disease. Executive summary. Conference proceeding for healthcare professions from a special writing group of the American Heart Association. Circulation 2002; 105: 2231-2239.
6. Hadour G, Ferrera R, Sebbag L, Forrat R, Delaye J, Lorgeril M: Improved myocardial tolerance to ischaemia in the diabetic rabbit. J Mol Cell Cardiol 1998; 30: 1869-1875.
7. Tatsumi T, Matoba S, Kobara M, et al: Energy metabolism after ischemic preconditioning in streptozotocin-induced diabetic rat hearts. J Am Coll Cardiol 1998; 31: 707-715.
8. Ishihara M, Inoue I, Kawagoe T, et al: Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol 2001; 38: 1007-1011.
9. Ishihara M, Sato H, Tateishi H, et al: Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis. J Am Coll Cardiol 1997; 30: 970-975.
10. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM: Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103: 3111-3116.
11. Klepzig H, Kober G, Matter C, et al: Sulfonylureas and ischaemic preconditioning. A double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439-446.
12. Connaughton M, Webber J: Diabetes and coronary artery disease: time to stop taking the tablets? Heart 1998; 80: 108-109.
13. Kremastinos DT, Bofilis E, Karavolias G, Papalois A, Kaklamanis L, Iliodromitis EK: Preconditioning limits myocardial infarct size in hypercholesterolemic rabbits. Atherosclerosis 2000; 150/1: 81-89.
14. Li G, Tokuno S, Tahepold P, Vaage J, Lowbeer C, Valen G: Preconditioning protects the severely atherosclerotic mouse heart. Ann Thorac Surg 2001; 71: 1296-1304.
15. Ueda Y, Kitakaze M, Komamura K, et al: Pravastatin restored the infarct size limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J Am Coll Cardiol 1999; 34: 2120-2125.
16. Pantos C, Malliopoulou V, Paizis I, et al: Thyroid hormone and cardioprotection: study of p38 MAPK JNKs during ischaemia and at reperfusion in isolated rat heart. Mol Cell Biochem 2003; 242: 173-180.
17. Gheeraert PJ, Henriques JPS, Buyzere ML, De Pauw M, Taeymans Y, Zijlstra F: Preinfarction angina protects against out-of-hospital ventricular fibrillation in patients with acute occlusion of the left coronary artery. J Am Coll Cardiol 2001; 38: 1369-1374.
18. Psychari SN, Iliodromitis EK, Hamodraka E, et al: Preinfarction angina does not alter infarct size and in hospital outcome after acute myocardial infarction with ST elevation, Int J Cardiol 2004; 94: 187-191.
19. Kloner RA, Shook T, Antman, EM, et al, and the TIMI-9B Investigators. Prospective temporal analysis of the onset of preinfarction angina versus outcome. An ancillary study in Timi-9B. Circulation 1998; 97: 1042-1045.
20. Iliodromitis EK, Papadopoulos C, Paraskevaidis IA, Kyriakides ZS, Flessa C, Kremastinos DT: Protection from preconditioning can be reinstated at various reperfusion intervals. Cardiovasc Drugs Ther 1996; 10: 341-346.
21. Iliodromitis EK, Kremastinos DT, Katritsis DG, Papadopoulos CC, Hearse DJ: Multiple cycles of preconditioning cause loss or protection in open-chest rabbits. J Mol Cell Cardiol 1997; 29: 915-920.
22. Lim R, Laskey WK: Ischemic preconditioning in unstable coronary syndromes; evidence for time dependence. J Am Coll Cardiol 1997; 30: 1460-1465.
23. Tomai F, Perino M, Ghini AS, et al: Exercise-induced myocardial ischemia triggers the early phase of preconditioning but not the late phase. Am J Cardiol 1999; 83: 586-588.
24. Lambiase PD, Edwards RJ, Cusack MR, Bucknall CA, Redwood SR, Marber MS: Exercise-induced ischemia initiates the second window of protection in humans independent of collateral recruitment. J Am Coll Cardiol 2003; 41: 1174-1182.
25. Nakano A, Cohen MV, Downey JM: Ischemic preconditioning. From basic mechanisms to clinical applications. Pharmacology & Therapeutics 200; 86: 263-275.
26. Patel DJ, Purcell HJ, Fox KM, on behalf of the CESAR 2 investigation: Cardioprotection by opening of the KATP channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. Eur Heart J 1999; 20: 51-57.
27. The IONA Study Group. Effect of nicorandil on coronary events in patients with stable anginal: the impact of nicorandil in angina (IONA) randomized trial. Lancet 2002; 359: 1269-1275.
28. Iliodromitis EK, Cokkinos P, Zoga A, Steliou I, Vrettou AR, Kremastinos DT: Oral nicorandil recaptures the waned protection from preconditioning in vivo. Br J Pharmacol 2003; 138: 1101-1106.
29. Mahaffey KW, Puma JA, Barbagelata A, et al, for the AMISTAD Investigators: Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction. J Am Coll 1999; 34: 1711-1720.
30. Iliodromitis EK, Gaitanaki C, Lazou A, et al: Dissociation of stress-activated protein kinase (p38-MAPK and JNKs) phosphorylation from the protective effect of preconditioning in vivo. J Mol Cell Cardiol 2002; 34: 1019-1028.
31. Iliodromitis EK, Miki T, Liu GS, Downey JM, Cohen MV, Kremastinos DT: The PKC activator PMA preconditions rabbit heart in the presence of adenosine receptor blockade: is 5′-nucleotidase important? J Mol Cell Cardiol 1998; 30: 2201-2211.
32. Sasaki N, Sato T, Ohler A, Rourke BO, Marban E: Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 2000; 101: 439-445.